Li and colleagues using the same GL261 intracranial mouse model and the same anti-TIM-3 antibody (Clone RMT3-23) as Kim et al. [100], observed a small yet significant increase in mouse survival compared to control treated mice, when 250 μg/mouse of an anti-murine TIM-3 antibody was administered at day 12, 15, and 18 post tumor cell implantation [124]. Here, HAVCR2 is linked to neoplasm.